RhumbLine Advisers
ARGS

RhumbLine Advisers’s Argos Therapeutics, Inc. ARGS Stock Holding History

RhumbLine Advisers’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,339
Closed -$12K – 3046
2017
Q1 		$12K Buy
+1,339
New +$84.7K ﹤0.01% 2844

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

RhumbLine Advisers's ARGS Position: Q2 2017 in Review

RhumbLine Advisers sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 1,339 shares — an estimated $12K sold.

RhumbLine Advisers first reported a position in ARGS in Q1 2017 and held it in 1 quarter. The position peaked at $12K in Q1 2017. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • RhumbLine Advisers reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 1,339 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $12K.
  • RhumbLine Advisers first reported a position in Argos Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • RhumbLine Advisers's Argos Therapeutics, Inc. position peaked at $12K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.